Amblard I, et al. - Researchers sought to ascertain the impact of cytoreduction surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) on survival, and compare it with conventional palliative chemotherapy for patients with peritoneal metastasis from biliary carcinoma (PMC). They searched a prospective multicenter international database retrospectively identifying 34 patients with PMC who underwent treatment with a potentially curative CRS/HIPEC between 1995 and 2015. Outcomes suggested the feasibility of treatment with CRS and HIPEC for biliary carcinoma with peritoneal metastasis. This treatment strategy may provide survival benefit vs to palliative chemotherapy.